
Innovent Biologics, Inc., a prominent biopharmaceutical company, has announced the successful outcome of its Phase 3 registrational study (CLEAR-1). The study evaluated picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, in Chinese patients with moderate to severe plaque psoriasis. Picankibart met all primary and key secondary endpoints, demonstrating significant efficacy and a favourable safety profile. The findings pave the way for a new drug application submission to the Center for Drug Evaluation (CDE) of the National Medical Product Administration (NMPA).
Like
Save
Share